MXPA02004598A - Compuestos novedosos para tratar diabetes y condiciones asociadas. - Google Patents

Compuestos novedosos para tratar diabetes y condiciones asociadas.

Info

Publication number
MXPA02004598A
MXPA02004598A MXPA02004598A MXPA02004598A MXPA02004598A MX PA02004598 A MXPA02004598 A MX PA02004598A MX PA02004598 A MXPA02004598 A MX PA02004598A MX PA02004598 A MXPA02004598 A MX PA02004598A MX PA02004598 A MXPA02004598 A MX PA02004598A
Authority
MX
Mexico
Prior art keywords
novel compounds
associated conditions
treat diabetes
adipose tissue
concentrations
Prior art date
Application number
MXPA02004598A
Other languages
English (en)
Inventor
Dey Debendranath
Original Assignee
Calyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calyx Therapeutics Inc filed Critical Calyx Therapeutics Inc
Publication of MXPA02004598A publication Critical patent/MXPA02004598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan compuestos que disminuyen las concentraciones de glucosa en sangre, disminuyen las concentraciones de trigliceridos en suero, disminuyen la presion sanguinea sistolica e incrementan la captacion de glucosa por tejido adiposo, pero que no afectan la expresion de PPAR-( por el tejido adiposo.
MXPA02004598A 1999-11-08 2000-11-08 Compuestos novedosos para tratar diabetes y condiciones asociadas. MXPA02004598A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/436,047 US6525093B1 (en) 1999-11-08 1999-11-08 Compounds to treat diabetes and associated conditions
PCT/US2000/030927 WO2001034094A2 (en) 1999-11-08 2000-11-08 Novel compounds to treat diabetes and associated conditions

Publications (1)

Publication Number Publication Date
MXPA02004598A true MXPA02004598A (es) 2004-09-10

Family

ID=23730883

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02004598A MXPA02004598A (es) 1999-11-08 2000-11-08 Compuestos novedosos para tratar diabetes y condiciones asociadas.

Country Status (10)

Country Link
US (2) US6525093B1 (es)
EP (1) EP1235785A4 (es)
JP (1) JP2004503464A (es)
KR (1) KR100855335B1 (es)
CN (1) CN1195728C (es)
AU (1) AU784702B2 (es)
CA (1) CA2390276A1 (es)
MX (1) MXPA02004598A (es)
NZ (1) NZ518830A (es)
WO (1) WO2001034094A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
SG165988A1 (en) * 2001-11-29 2010-11-29 Theracos Inc Compounds for treatment of inflammation, diabetes and related disorders
ITRM20020014A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
EP1594837A1 (en) * 2003-02-12 2005-11-16 Galderma Research & Development, S.N.C. Compounds which are modulators of the ppar-type receptors and their use in cosmetic or pharmaceutical compositions
FR2850967B1 (fr) * 2003-02-12 2007-04-13 Galderma Res & Dev NOUVEAUX COMPOSES MODULATEURS DES RECEPTEURS DE TYPE PPARs ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES
FR2850968B1 (fr) * 2003-02-12 2007-04-13 Galderma Res & Dev NOUVEAUX COMPOSES MODULATEURS DES RECEPTEURS DE TYPE PPARs ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES
CA2512757A1 (en) * 2003-02-12 2004-08-26 Galderma Research & Development, S.N.C. Compounds which are modulators of the ppar-type receptors and their use in cosmetic or pharmaceutical compositions
ES2299906T3 (es) * 2003-11-25 2008-06-01 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisomas.
CA2573761A1 (en) * 2004-07-14 2006-02-23 Janssen Pharmaceutica N.V. Use of estrogen related receptor-modulating aryl ethers
US9932319B2 (en) 2013-05-28 2018-04-03 Empire Technology Development Llc Antioxidant humic acid derivatives and methods of preparation and use
WO2014193338A1 (en) 2013-05-28 2014-12-04 Empire Technology Development Llc Humic acid derivatives and methods of preparation and use
WO2014209369A1 (en) 2013-06-28 2014-12-31 Empire Technology Development Llc Edible plasticizers for food and food packaging films

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110470A (en) * 1965-10-07 1978-08-29 Horst Kummer Pharmaceutical composition comprising d,l-α-methyl-thyroxine ethyl ester and the salts thereof and the control of cholesterol and triglyceride blood level therewith
US3683009A (en) 1968-10-10 1972-08-08 Du Pont {60 , {62 -bis(trifluoromethyl) stilbenes
US3609183A (en) 1969-01-08 1971-09-28 Parke Davis & Co {60 -{8 {11 -(dimethylaminoalkyl)phenyl{9 -4-methoxy-{60 {40 -nitrostilbene compounds
US4312855A (en) 1970-11-16 1982-01-26 Colgate-Palmolive Company Compositions containing aminopolyureylene resin
US3857955A (en) * 1971-03-29 1974-12-31 Lilly Co Eli Anti-inflammatory agents
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
JPS6045632B2 (ja) 1978-03-09 1985-10-11 三菱化学株式会社 ω−アミノアルコキシスチルベン類及びその酸付加塩
US4284637A (en) 1978-03-09 1981-08-18 Mitsubishi Chemical Ind., Limited Pharmaceutically active 2-(4-aminobutoxy)stilbenes
DE2832213A1 (de) 1978-07-21 1980-01-31 Bayer Ag Stilbenderivate, verfahren zu ihrer herstellung und ihre verwendung als insektizide
JPS5629548A (en) 1979-08-16 1981-03-24 Mitsubishi Chem Ind Ltd Omega-aminoalkoxystilbenes and their acid addition salts
SE427983B (sv) * 1980-02-15 1983-05-30 Pripps Bryggerier Ab Dryckesprodukt
US4389416A (en) * 1981-10-09 1983-06-21 Abbott Laboratories Diphenyl ether, diphenyl thioether and diphenyl methane phenol mannich bases
FR2562539B1 (fr) 1984-04-06 1987-04-17 Chauvin Blache Lab Nouveaux derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications en therapeutique et comme ligands
US4716905A (en) 1985-09-25 1988-01-05 Fluorochrome, Inc. Method of retrograde fluorescent labeling of neurons
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4992576A (en) * 1987-01-12 1991-02-12 Eli Lilly And Company Intermediates for leukotriene antagonists
JPS63290842A (ja) * 1987-05-25 1988-11-28 Maruzen Petrochem Co Ltd ２−（置換フェニル）プロピオン酸またはそのアルキルエステルの製造法
GB8716650D0 (en) 1987-07-15 1987-08-19 Ici Plc Use of olefinic compounds
US5250562A (en) 1988-02-24 1993-10-05 Hoffmann-La Roche Inc. Stilbene derivatives
CA1340955C (en) 1988-02-24 2000-04-11 Michael Klaus Stilbene derivatives
DE3926148A1 (de) 1989-08-08 1991-02-28 Basf Ag Diarylacetylene, ihre herstellung und verwendung
US5189056A (en) 1989-12-19 1993-02-23 University Of North Carolina At Chapel Hill Protection of moist stratified squamous epithelia against damage from noxious luminal agents
US5162337A (en) 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
DK0498095T3 (da) 1991-02-05 1995-06-19 Merrell Dow Pharma Sulfoniske stilbenderivater til behandling af virussygdomme
CH683151A5 (de) 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
US5171753A (en) 1991-05-15 1992-12-15 A. H. Robins Company, Incorporated Derivatives of 2-amino-1-phenylethanol having antiulcer activity
EP0620822B1 (en) 1991-11-07 2001-05-30 Nanotronics, Inc. Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system
US5246936A (en) 1991-12-20 1993-09-21 American Cyanamid Company Methods and compositions containing pesticides and stilbene compounds for enhanced pesticidal activity
US5314693A (en) 1992-02-07 1994-05-24 Kioritz Corporation Pest control chemicals against pine wood nematodes
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
AU669279B2 (en) 1993-03-10 1996-05-30 Morinaga Milk Industry Company Limited Stilbene derivative and stilbene analog derivative, and use thereof
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
IT1264988B1 (it) 1993-12-14 1996-10-17 Sigma Prod Chim Composizioni cosmetiche e dermatologiche per la protezione da radiazioni uv contenenti derivati dallo stilbene
TW308598B (es) 1994-01-14 1997-06-21 Hoffmann La Roche
US5559151A (en) 1994-11-30 1996-09-24 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
CA2174582A1 (en) 1995-05-05 1996-11-06 Alexander Chucholowski Sulphuric acid esters of amino-sugars
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5770620A (en) 1995-06-19 1998-06-23 Ontogen Corporation Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
US5827898A (en) 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes

Also Published As

Publication number Publication date
AU1760701A (en) 2001-06-06
JP2004503464A (ja) 2004-02-05
US6525093B1 (en) 2003-02-25
CA2390276A1 (en) 2001-05-17
CN1413184A (zh) 2003-04-23
US20020107285A1 (en) 2002-08-08
CN1195728C (zh) 2005-04-06
WO2001034094A3 (en) 2002-04-25
WO2001034094A2 (en) 2001-05-17
EP1235785A4 (en) 2004-11-24
KR100855335B1 (ko) 2008-09-04
US6855732B2 (en) 2005-02-15
NZ518830A (en) 2005-09-30
EP1235785A2 (en) 2002-09-04
KR20020062739A (ko) 2002-07-29
WO2001034094A9 (en) 2002-07-25
AU784702B2 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
MXPA02007639A (es) Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
MXPA02004598A (es) Compuestos novedosos para tratar diabetes y condiciones asociadas.
SE9702860D0 (sv) New use
WO2006044556A3 (en) Dual inhibitors of lipoxygenase for treating diabetes
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
ATE312635T1 (de) Ventilanordnung
ATE281839T1 (de) Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut
PT1112275E (pt) Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
EP1742643A4 (en) MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOKASE EXPRESSION
WO2006114105A8 (en) Use of modified factor vii for treating bleeding
WO2006138537A3 (en) Ex vivo blood treatment with renal epithelial cells in cardiorenal and hepatorenal syndrome
HK1121083A1 (en) Methods for reducing blood pressure
EA200600402A1 (ru) Клеточные стенки дрожжей для лечения или профилактики гипергликемии или для стабилизации уровня сахара в крови
BG106434A (en) Pharmacological subtance
AU8759298A (en) Use of nordihydroguaiaretic acid to lower serum triglycerides, blood pressure and to treat syndrome
WO2004053107A3 (en) Methods for treating diabetes
WO2003032804A3 (en) Reversing or preventing premature vascular senescence
IS5231A (is) Vefjaþáttur sem hefur áhrif á blóðæðarmyndun
WO2000054760A3 (en) Bicyclo (3.3.1) nonenes useful for the treatment of diabetes and hypertriglyceridemia
WO2001042438A3 (en) Leukolysin/mmp25/mt6-mmp
DE602004027515D1 (de) Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz
GB9818650D0 (en) Therapeutic compounds and methods of making and using the same
AU2003259006A1 (en) Composition and method for use in intestinal cleansing procedures
PT1305020E (pt) Utilizacao de fibratos para a preparacao de um medicamento util no tratamento da insuficiencia cardiaca congestiva

Legal Events

Date Code Title Description
FG Grant or registration